N-glycoloyl-glycine ethyl ester | 500363-74-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-glycoloyl-glycine ethyl ester
• 英文别名: Oxyacetyl-aminoessigsaeure-aethylester；Oxyacetyl-glycin-aethylester；N-Glykoloyl-glycin-aethylester；Glycine, N-(hydroxyacetyl)-, ethyl ester；ethyl 2-[(2-hydroxyacetyl)amino]acetate
• CAS: 500363-74-6
• 化学式: C₆H₁₁NO₄
• 分子量: 161.158
• InChiKey: UUXJPXYHJLRVEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 水 作用下， 生成 N-glycoloyl-glycine ethyl ester
  参考文献：
  名称：

  Curtius; Darapsky, Chemische Berichte, 1906, vol. 39, p. 1378

  摘要：

  DOI：

文献信息

• PHOSPHODIESTERASE IV INHIBITOR CONTAINING PYRIDYLACRYLAMIDE DERIVATIVE
  申请人：TSUMURA & CO.

  公开号：EP1495757A1

  公开（公告）日：2005-01-12

  This invention relates to a phosphodiesterase IV inhibitor containing as an active ingredient a pyridylacrylamide derivative represented by the following formula (I): (wherein Ar1 represents substituted or unsubstituted pyridyl; Ar2 represents phenyl substituted by alkoxy, etc.; R1 represents hydrogen, alkyl, or aryl; R2 represents hydrogen, alkyl, cyano, or alkoxycarbonyl; R3 represents hydrogen or optionally substituted alkyl; X represents oxygen or sulfur; A and B are the same or different and each independently represents hydrogen, hydroxyl, alkoxy, or alkylthio, or A and B together represent oxo, thioxo, etc., or A may be hydroxyl and B may be 1-alkylimidazol-2-yl; and n is an integer from 1 to 3) or a pharmaceutically acceptable salt thereof.

  这项发明涉及一种磷酸二酯酶IV抑制剂，其活性成分为以下式(I)所代表的吡啶丙烯酰胺衍生物：（其中Ar1代表取代或未取代的吡啶；Ar2代表被烷氧基等取代的苯基；R1代表氢、烷基或芳基；R2代表氢、烷基、氰基或烷氧羰基；R3代表氢或可选择取代的烷基；X代表氧或硫；A和B相同或不同，每个独立代表氢、羟基、烷氧基或烷基硫基，或A和B一起代表氧代、硫代等，或A可能是羟基，B可能是1-烷基咪唑-2-基；n为1至3的整数）或其药学上可接受的盐。
• Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
  申请人：Meyers J. Marvin

  公开号：US20050101623A1

  公开（公告）日：2005-05-12

  The present invention provides novel bridged beta-carboline compounds that are capable of inhibiting mitogen activated protein kinase-activated protein kinase-2 and analogues thereof and pharmaceutical compositions and kits that include these compounds.

  本发明提供了新型的桥接β-喹啉衍生物，能够抑制有丝分裂原活化蛋白激酶激活蛋白激酶-2及其类似物，并且包括这些化合物的制药组合物和试剂盒。
• Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative
  申请人：Hattori Tomohisa

  公开号：US20050187264A1

  公开（公告）日：2005-08-25

  This invention relates to a phosphodiesterase IV inhibitor containing as an active ingredient a pyridylacrylamide derivative represented by the following formula (I): (wherein Ar 1 represents substituted or unsubstituted pyridyl; Ar 2 represents phenyl substituted by alkoxy, etc.; R 1 represents hydrogen, alkyl, or aryl; R 2 represents hydrogen, alkyl, cyano, or alkoxycarbonyl; R 3 represents hydrogen or optionally substituted alkyl; X represents oxygen or sulfur; A and B are the same or different and each independently represents hydrogen, hydroxyl, alkoxy, or alkylthio, or A and B together represent oxo, thioxo, etc., or A may be hydroxyl and B may be 1-alkylimidazol-2-yl; and n is an integer from 1 to 3) or a pharmaceutically acceptable salt thereof.

  本发明涉及一种磷酸二酯酶IV抑制剂，其作为活性成分包含以下式(I)所表示的吡啶基丙烯酰胺衍生物：（其中Ar1表示取代或未取代的吡啶基；Ar2表示被烷氧基等取代的苯基；R1表示氢、烷基或芳基；R2表示氢、烷基、氰基或烷氧羰基；R3表示氢或可选择取代的烷基；X表示氧或硫；A和B相同或不同，每个独立地表示氢、羟基、烷氧基或烷基硫，或A和B在一起表示氧代、硫代等，或A可以是羟基，B可以是1-烷基咪唑-2-基；n为1至3的整数）或其药学上可接受的盐。
• NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS
  申请人：Guedat Philippe

  公开号：US20090215786A1

  公开（公告）日：2009-08-27

  The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.

  本发明涉及一种新的化合物(I)的配方、制备方法及其治疗用途。
• PYRIDYLACRYLAMIDE DERIVATIVES AND NEPHRITIS REMEDIES AND TGF-$g(b) INHIBITORS CONTAINING THE SAME
  申请人：TSUMURA & CO.

  公开号：EP1000935A1

  公开（公告）日：2000-05-17

  The present invention relates to an agent for treating nephritis and a TGF-β inhibiting agent comprising as an effective ingredient a pyridylacrylamide derivative represented by the following formula (I): wherein Ar1 is a substituted or unsubstituted pyridyl group, Ar2 is a substituted or unsubstituted phenyl group, R1 is a hydrogen atom, an alkyl group or an aryl group, R2 is a hydrogen atom, an alkyl group, a cyano group or an alkoxycarbonyl group, R3 is a hydrogen atom or an optionally substituted alkyl group, X is an oxygen or sulfur atom. A and B are same or different and each represent a hydrogen atom, a hydroxyl group, an alkoxy group or an alkylthio group, or A and B together form an oxo or thioxo group, or a group represented by the formula: =N-Y in which Y is a dialkylamino, hydroxyl, aralkyloxy or alkoxy group, or a group represented by the formula: -Z1-M-Z2- in which Z1 and Z2 are same or different and each represent an oxygen or sulfur atom or an imino group optionally substituted by an alkyl group, and M is an alkylene group or a 1,2-phenylene group, or A is a hydroxyl group and B is a 1-alkylimidazol-2-yl group, and n is an integer of 1 to 3, or a pharmaceutically acceptable salt thereof; as well as the pyridylacrylamide derivatives.

  本发明涉及一种治疗肾炎的制剂和一种 TGF-β 抑制剂，其有效成分包括下式 (I) 所代表的吡啶丙烯酰胺衍生物： 其中 Ar1 是取代或未取代的吡啶基，Ar2 是取代或未取代的苯基，R1 是氢原子、烷基或芳基，R2 是氢原子、烷基、氰基或烷氧羰基，R3 是氢原子或任选取代的烷基，X 是氧原子或硫原子。A 和 B 相同或不同，各自代表一个氢原子、一个羟基、一个烷氧基或一个烷硫基，或 A 和 B 共同形成一个氧代或硫代基团，或一个由式：=N-Y 所代表的基团，其中 Y 是一个二烷基氨基、羟基、芳氧基或烷氧基，或一个由式： -Z1-M-Z2- 所代表的基团，其中 Y 是一个二烷基氨基、羟基、芳氧基或烷氧基：-Z1-M-Z2-，其中 Z1 和 Z2 相同或不同，且各自代表氧原子或硫原子或任选被烷基取代的亚氨基，M 为亚烷基或 1,2-亚苯基，或 A 为羟基，B 为 1-烷基咪唑-2-基，n 为 1 至 3 的整数、 或其药学上可接受的盐；以及吡啶丙烯酰胺衍生物。